Dr. Tagawa On Next Steps With Sacituzumab Govitecan In Advanced Urothelial Carcinoma

Dr. Tagawa on Next Steps With Sacituzumab Govitecan in Advanced Urothelial Carcinoma

Dr. Tagawa on Sacituzumab Govitecan in Urothelial Carcinoma

Antibody-drug conjugates in advanced urothelial cancer: sacituzumab govitecan

Sacituzumab govitecan in the treatment of metastatic urothelial carcinoma

Use of Sacituzumab Govitecan in Metastatic Urothelial Carcinoma

Targeted Oncology

Sacituzumab Govitecan Given Accelerated FDA Approval for Advanced Urothelial Cancer

Grand Rounds in Urology

Sacituzumab govitecan in patients with previously treated metastatic urothelial cancer

Efficacy of sacituzumab govitecan in mUC by Trop-2 expression

Sacituzumab govitecan plus enfortumab vedotin in advanced urothelial cancer

Dr. Tagawa on Next Steps for Taxanes in Prostate Cancer

Biomarker data point to wide use of sacituzumab govitecan in advanced TNBC | Sara Hurvitz

Medicine Matters oncology

Sacituzumab Govitecan for Patients With Advanced Urothelial Carcinoma

Sacituzumab govitecan in metastatic urothelial carcinoma: updates on the Phase II study

Dr. Bardia on Sacituzumab Govitecan in Triple-Negative Breast Cancer

Dr. Scott Tagawa Discusses IMMU-132 in Patients With Urothelial Carcinoma

Phase III TROPICS-04 trial: sacituzumab govitecan vs treatment of choice in advanced mUC

Petros Grivas on the Efficacy of Sacituzumab Govitecan for Bladder Cancer

GU Oncology Now

Improving Patient Outcomes in Urothelial Carcinoma With Novel Antibody–Drug Conjugates

PeerView Oncology

TROPHY-U-01: Sacituzumab govitecan in patients with mUC after failure of platinum-based regimens...

MedNews Week Keynote Conference - Dr. Scott T. Tagawa (Weill Cornell Medicine) - Prostate Cancer